Telaprevir user's guide

Liver International

Volumn 32, Issue SUPPL. 1, 2012, Pages 17-25

  Liapakis, Ann Marie ^a   Jacobson, Ira ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hepatitis C virus; Interferon; Protease inhibitor; Ribavirin; Telaprevir

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANEMIA; ANTIVIRAL THERAPY; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; MONOTHERAPY; NAUSEA; PRURITUS; RELAPSE; RESPONSE GUIDED THERAPY; REVIEW; SIDE EFFECT; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84855252404     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02708.x     Document Type: Review

References (23)

1. Dienstag JL, McHutchinson JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
2. World Health Organization. Hepatitis C. World HealthOrganization, 2000. Available at: Accessed 1 April 2011.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
4. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36(Suppl): S30-4.
5. Ghany MG, Strader DB, Thomas DL, et al. AASLD practice guidelines: diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
6. Jacobson IM. Treatment options for patients with chronic hepatitis C not responding to antiviral therapy. Clin Gastroenterol Hepatol 2009; 7: 921-30.
7. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitisC virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
8. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.
9. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C viral life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979-98.
10. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002.
11. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha2a inhibit wild-type and resistant genotype 1 hepatitis c virus replication in patients. Hepatology 2007; 46: 631-9.
12. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640-8.
13. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49: 163-9.
14. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
15. Hezode C, Forestier N, Dushieko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
16. McHutchison JG, Manns MP, Muir AJ, et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
17. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Eng J Med 2011; 364: 2405-16.
18. Kieffer TL, Bartels D, Sullivan J, et al. Clinical virology results from telaprevir phase 3 study ADVANCE. 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2010). Boston (MA), October 29 to November 2, 2010 [abstract: ID#LB-11].
19. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
20. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Eng J Med 2011; 364: 2417-28.
21. Foster GR, Zeuzem S, Andreone P, et al. Subanalyses of the telaprevir lead-in arm in the REALIZE Study: response at week 4 is not a substitute for prior null response categorization. J Hepatology 2011; 54(Suppl. 1): S3.
22. Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010). Boston (MA), October 29 to November 2, 2010 [abstract: 227].
23. ™) Package Insert, Vertex Pharmaceuticals.